Toward a Single-Dose Cure for Buruli Ulcer
Sangeeta Susan Thomas, Nitin Pal Kalia, Marie‐Thérèse Ruf, Gerd Pluschke, Kévin Pethe
Antimicrobial Agents and Chemotherapy · 2020-07
Abstract
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
MeSH terms
- Buruli ulcer
- Mycobacterium ulcerans
- Medicine
- Tuberculosis
- Mycobacterium tuberculosis
- Skin ulcer
- Dermatology
- Disease
- Internal medicine